85-LB: Freestyle Libre System Use Associated with Reduction in Acute Diabetes Events and All-Cause Hospitalizations in Patients with Type 2 Diabetes without Bolus Insulin

Data on the benefit of continuous glucose monitors (CGM) in people with diabetes not using intensive insulin therapy is limited. We describe clinical outcomes after a FreeStyle Libre® system purchase in people with type 2 diabetes (T2D) not using bolus insulin. IBM MarketScan™ Commercial Claims and Medicare Supplemental databases were used in this retrospective, observational analysis. MarketScan contains insurance billing claims for inpatient, outpatient, and pharmacy. Cohort requirements included: de novo CGM, FreeStyle Libre system purchase 2017 Q4-2018 Q4, T2D diagnosis, ≥18 years old, no fast-/short-acting insulin, ≥6-months pre-index observation time. Primary outcome was acute diabetes events (ADE): hospitalization with hyper-/hypoglycemia as primary diagnosis or outpatient emergency with same codes. Secondary outcome was all-cause hospitalization. Andersen-Gill Cox regression compared event rates 6-months pre-/post-index. The cohort (n= 7,167, age 53.3±9.5 years, 51.5% male, avg. post-index follow-up 155 days) saw a reduction in ADE from 0.071 to 0.052 events/pt-yr (HR: 0.70 [0.57 0.85]; P: